Patients with acute myeloid leukemia in complete cytological remission with intermediate or high risk prognosis according to ELN 2017
Patients with myelodysplasia according to the WHO 2016 definition, with IPSS ≥1.5 and disease status is : stable or in partial response or complete response according to IWG 2006.
Patients with indication of first allo-HSCT with a matched related or unrelated donor
Patients receiving non-myeloablative or reduced toxicity conditioning
Patients affiliated to a social security scheme
Patients who have received a complete information on the organization of the research and signed his informed consent
You may not be if
Patients with an alternative donor (HLA 5/10 or unit cord blood)
Patients with another active cancer or a history of cancer diagnosed in the previous 5 years
Patients with uncontrolled infection at the time of inclusion, or with positive HIV (1 + 2) or HTLV (1 + 2), Hepatitis C or active hepatitis B
Patients referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code.
Clareo Health | Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
